Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Kofarest DX
- Development stage
- Unknown
- Lead developer
- Centaur Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Kofarest DX is an oral combination syrup developed by Centaur Pharmaceuticals for the treatment of dry, non-productive coughs associated with allergies, smoking, infections, or throat irritation. It contains three active ingredients: dextromethorphan hydrobromide, a cough suppressant that acts on the central nervous system to elevate the cough threshold; chlorpheniramine maleate, a first-generation antihistamine that blocks histamine H1 receptors to relieve allergic symptoms such as sneezing, runny nose, and watery eyes; and menthol, which provides a cooling sensation to soothe throat irritation. The combination is approved and marketed in India.
- Brand names
- Kofarest DXKofarest DX LinctusKofarest-DXKofarest-DX Linctus
- Other names
- chlorpheniramine + dextromethorphan + mentholchlorpheniramine maleate + dextromethorphan hydrobromide + menthol
02
Targets
HRH1 (Histamine H1 Receptor)Nicotinic Acetylcholine ReceptorSERT (Sodium-dependent serotonin transporter)SIGMAR1 (Sigma non-opioid intracellular receptor 1)TMEM97 (Sigma-2 receptor complex (TMEM97/PGRMC1))TRPM8 (Transient receptor potential cation channel subfamily M member 8)NMDAR (Glutamate receptor ionotropic, NMDA)
Beyond the preview
Go deeper on Kofarest DX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Kofarest DX.